# EDGAR Filing Document

**Accession Number:** 0002102720
**File Stem:** 0001213900-26-069143
**Filing Date:** 2026-6
**Character Count:** 68204
**Document Hash:** e38b1a76613b39cbe2b1c92dbeabfcbb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-069143.hdr.sgml**: 20260616

**ACCESSION NUMBER**: 0001213900-26-069143

**CONFORMED SUBMISSION TYPE**: F-1/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260616

**DATE AS OF CHANGE**: 20260616

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tarsier Pharma Ltd.
- **CENTRAL INDEX KEY:** 0002102720
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** F-1/A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-295210
- **FILM NUMBER:** 261093592

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 10 HAMA'APILIM ST.
- **CITY:** ZICHRON YAACOV
- **PROVINCE COUNTRY:** L3
- **ZIP:** 3093765
- **BUSINESS PHONE:** 972-4-639-8050

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 10 HAMA'APILIM ST.
- **CITY:** ZICHRON YAACOV
- **PROVINCE COUNTRY:** L3
- **ZIP:** 3093765

#### As filed with the Securities and Exchange Commission on June 16 , 2026.

#### Registration Number 333-295210

#### UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549

#### ______________________

#### AMENDM ENT NO. 3

#### T O<br> FORM F-1<br> REGISTRATION STATEMENT <br>UNDER <br>THE SECURITIES ACT OF 1933<br> ______________________

#### Tarsier Pharma Ltd.<br> (Exact Name of Registrant as Specified in its Charter)

#### ______________________

---

| | | |
|:---|:---|:---|
|  **State of Israel** | **2834** | **N/A** |
|  (State or other jurisdiction of<br>incorporation or organization) | (Primary Standard Industrial <br>Classification Code Number) | (I.R.S. Employer <br>Identification No.) |

---

#### 10 HaMa'apilim St.<br>Zichron Yaacov, Israel 3093765<br> Tel: + 972-4-639-8050
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)

#### ______________________

#### Puglisi & Associates<br>850 Library Ave., Suite 204<br>Newark, DE 19711<br>Tel: (302) 738-6680
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)

#### ______________________

#### with copies to:

---

| | | |
|:---|:---|:---|
|  **Barry I. Grossman, Esq. <br>Justin Grossman, Esq. <br>Nahal A. Nellis, Esq. <br>Ellenoff Grossman & Schole LLP** <br>**1345 Avenue of the Americas** <br>**New York, NY 10105** <br>**(212) 370**-1300 | **Yael Shimon**-Many**, Adv. <br>Benjamin Waltuch, Adv., <br>Yuval Mor, Adv., <br>Pearl Cohen Zedek Latzer Baratz, <br>121 Menachem Begin Rd., 53**<sup>rd</sup> **Floor <br>Tel Aviv**-Jaffa**, Israel 6701203 <br>+972**-3-303-9000 | **Joseph M. Lucosky, Esq. <br>Lawrence Metelitsa, Esq. <br>Sebastian A. Bacon, Esq. <br>Lucosky Brookman LLP <br>101 Wood Avenue South <br>Woodbridge, New Jersey 08830 <br>(732) 395**-4400 |

---

#### ______________________

#### Approximate date of commencement of proposed sale to public: <br> As soon as practicable after the effective date hereof.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

Emerging growth company ☒

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

____________

† The term "new or revised financial accounting standard" refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

**The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.**

------

#### EXPLANATORY NOTE
This Amendment No. 3 is being filed solely for the purpose of filing Exhibit 10.10 to this registration statement on Form F-1, or the Registration Statement, and to amend and restate the exhibit index set forth in Part II of the Registration Statement. No changes have been made to the Registration Statement other than this explanatory note as well as revised versions of the cover page and Part II of the Registration Statement. This Amendment No. 3 does not contain copies of the prospectus included in the Registration Statement, which remains unchanged from the Registration Statement filed on June 8, 2026, and consists only of the cover page, this explanatory note and Part II of the Registration Statement.

------

#### PART II — INFORMATION NOT REQUIRED IN PROSPECTUS

#### Item 6. Indemnification of Directors and Officers

#### Indemnification
The Israeli Companies Law, 5759-1999 (the "Companies Law"), and the Israeli Securities Law, 5728-1968 (the "Securities Law"), provide that a company may indemnify an office holder against the following liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a financial liability imposed on him or her in favor of another person by any judgment concerning an act performed in his or her capacity as an office holder, including a settlement or arbitrator's award approved by a court;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reasonable litigation expenses, including attorneys' fees, expended by the office holder (a) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (1) no indictment (as defined in the Companies Law) was filed against such office holder as a result of such investigation or proceeding; and (2) no financial liability as a substitute for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; or (b) in connection with a monetary sanction;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reasonable litigation expenses, including attorneys' fees, expended by the office holder or imposed on him or her by a court,: (1) in proceedings that the company institutes, or that another person institutes on the company's behalf, against him or her; (2) in a criminal proceedings of which he or she was acquitted; or (3) as a result of a conviction for a crime that does not require proof of criminal intent; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• expenses incurred by an office holder in connection with an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys' fees. An "Administrative Procedure" is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.

The Companies Law also permits a company to undertake in advance to indemnify an office holder, provided that if such indemnification relates to financial liability imposed on him or her, as described above, then the undertaking should be limited and shall detail the following foreseen events and amount or criterion:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• to events that in the opinion of the board of directors can be foreseen based on the company's activities at the time that the undertaking to indemnify is made; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• in amount or criterion determined by the board of directors, at the time of the giving of such undertaking to indemnify, to be reasonable under the circumstances.

We will enter into indemnification agreements with all of our directors and with all members of our senior management. Each such indemnification agreement provides the office holder with indemnification permitted under applicable law and up to a certain amount, and to the extent that these liabilities are not covered by directors and officers insurance.

#### Exculpation
Under the Companies Law, an Israeli company may not exculpate an office holder from liability for a breach of his or her duty of loyalty, but may exculpate in advance an office holder from his or her liability to the company, in whole or in part, for damages caused to the company as a result of a breach of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated articles of association provide that we may exculpate, in whole or in part, any office holder

from liability to us for damages caused to the company as a result of a breach of his or her duty of care, but prohibit an exculpation from liability arising from a company's transaction in which our controlling shareholder or officer has a personal interest. Subject to the aforesaid limitations, under the indemnification agreements, we exculpate and release our office holders from any and all liability to us related to any breach by them of their duty of care to us to the fullest extent permitted by law.

#### Limitations
The Companies Law provides that the Company may not exculpate or indemnify an office holder nor enter into an insurance contract that would provide coverage for any liability incurred as a result of any of the following: (1) a breach by the office holder of his or her duty of loyalty unless (in the case of indemnity or insurance only, but not exculpation) the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was carried out intentionally or recklessly (as opposed to merely negligently); (3) any act or omission committed with the intent to derive an illegal personal benefit; or (4) any fine, monetary sanction, penalty or forfeit levied against the office holder.

Under the Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders.

Our amended and restated articles of association permit us to exculpate (subject to the aforesaid limitation), indemnify and insure our office holders to the fullest extent permitted or to be permitted by the Companies Law.

#### Item 7. Recent Sales of Unregistered Securities
Set forth below are the sales of all securities by the Company during the last three years, which were not registered under the Securities Act. The Company believes that each of such issuances was exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act, Rule 701 and/or Regulation S under the Securities Act. No underwriters were involved in these issuances of these securities.

In 2024, the Company completed a financing round by issuing SAFEs in an aggregate amount of $2,200,000 to certain accredited investors. Of these 2024 SAFEs, $300,000 were issued SAFEs on the same terms as the 2022 SAFEs (the "2024 Parity SAFEs"), all of which were converted between January 22, 2026 and February 2, 2026 into an aggregate of 100,020 ordinary shares to holders of such 2024 Parity SAFEs, upon their maturity based on the Maturity Conversion Terms (which are identical to those included in the 2022 SAFEs). We refer to these as the "2024 Parity SAFEs."

During November 2025 the investor of the remaining $1,900,000 of SAFEs issued in 2024 (the "2024 SAFEs") opted to utilize the 'Most Favored Nation' clause included in the 2024 SAFEs, such that the 2024 SAFEs were amended and restated into the form of the November 2025 SAFE (see details below). We refer to these as the "Amended 2024 SAFEs."

In 2025, the Company completed two financing rounds in May 2025 and November and December 2025 by issuing SAFEs in an aggregate amount of $2,100,000 to certain accredited investors (collectively, the "2025 SAFEs").

In May 2025 the Company issued one SAFE in the amount of $100,000, which entitles its holder, in the case of an equity financing prior to its termination (or the termination of the November 2025 SAFEs referred to below), to conversion based on the price per share of the shares sold in the equity financing multiplied by 80%. We refer to this SAFE as the "May 2025 SAFE." The sale of this SAFE also included, in the event of the occurrence of an equity financing, a warrant equal to one hundred percent (100%) of the holder's SAFE purchase amount and exercisable at the conversion price of the May 2025 SAFE, and with a term of two years from such equity financing. We refer to this warrant as the "May 2025 SAFE Warrant." The May 2025 SAFE Warrant is issued upon and subject to the occurrence of an "equity financing" and its term is calculated beginning from the occurrence of such equity financing and for two years thereafter. The term "equity financing" in this SAFE includes our initial public offering, which is the offering contemplated by this prospectus.

In November and December 2025, the Company issued SAFEs in the amount of $2,000,000 which entitled their holders, in the case of an equity financing prior to the termination of the 2025 SAFEs, to convert such holder's 2025 SAFE based on the lower of: (1) the price per share of the shares sold in the equity financing multiplied by 75% or (ii) a price per share reflecting a Company's pre money valuation of $115,000,000 on a fully diluted basis. We refer

to these as the "November 2025 SAFEs." Prior to the date of our audit report for the fiscal year ended December 31, 2024, which audit report was dated December 21, 2025 and included elsewhere in this prospectus, the amount of November 2025 SAFEs consisted of $1,850,000. Subsequent to December 21, 2025 being such date of our audit report for the fiscal year end 2024, an additional $150,000 in November 2025 SAFEs were subscribed for by an investor on December 22, 2025, and which we refer to as the "Subsequent December 2025 SAFEs" (and which are included in the aggregate principal amount of $2,000,000 of our November 2025 SAFEs referred to in this prospectus).

Additionally, the sale of the November 2025 SAFEs included, in the event of occurrence of an equity financing, a warrant for each such SAFE equal to two hundred percent (200%) of the holder's SAFE purchase amount and exercisable at the conversion price of the November 2025 SAFEs, and with a term of three years from the date of such equity financing. We refer to these warrants as the "November 2025 SAFEs Warrants." Each of the November 2025 SAFEs Warrants is issued upon and subject to the occurrence of an "equity financing" (as defined in such SAFEs) and its term is calculated beginning from the occurrence of such equity financing and for three years thereafter. The term "equity financing" in these November 2025 SAFEs includes our initial public offering, which is the offering contemplated by this prospectus.

In connection with and upon the consummation of the Company's initial public offering, the Company will issue an aggregate of 927,449 ordinary shares relating to the exercise of the Amended 2024 SAFEs, May 2025 SAFE and November 2025 SAFEs to the holders of such SAFEs.

As referenced above during the last three years, since January 2023, we have granted to our directors, officers, consultants and employees under our Global Share Incentive Plan (2018) (the "2018 Incentive Plan") options exercisable for an aggregate of 2,865,550 of our ordinary shares, and these options have a weighted average exercise price of $1.45 per share, and the Company issued 8,900 ordinary shares upon exercise of options under its 2018 Incentive Plan.

The foregoing information gives effect to the contemplated share split of 1 to 10 referenced in the prospectus.

#### Item 8. Exhibits and Financial Statement Schedules.
**(a) Exhibits.**

---

| | |
|:---|:---|
|  **Exhibit No.** | **Description of document** |
|  1.1\* | [Form of Underwriting Agreement](http://www.sec.gov/Archives/edgar/data/2102720/000121390026066188/ea027016609ex1-1.htm) |
|  3.1\* | [Articles of Association of the Registrant, as currently in effect](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex3-1.htm) |
|  3.2\* | [Form of Amended and Restated Articles of Association of the Registrant, as effective immediately prior to the completion of this offering](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex3-2.htm) |
|  4.1\* | [Registrant's Specimen Certificate for Ordinary Shares](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex4-1.htm) |
|  4.2\* | [Form of Underwriter Warrant](http://www.sec.gov/Archives/edgar/data/2102720/000121390026066188/ea027016609ex4-2.htm) |
|  4.3\* | [Form of 2022 SAFE Agreement](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex4-3.htm) |
|  4.4\* | [Form of 2024 SAFE Agreement](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex4-4.htm) |
|  4.5\* | [Form of May 2025 SAFE Agreement](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex4-5.htm) |
|  4.6\* | [Form of November 2025 SAFE Agreement](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex4-6.htm) |
|  4.7\* | [Form of May 2025 SAFE Warrant](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex4-7.htm) |
|  4.8\* | [Form of November 2025 SAFE Warrant](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex4-8.htm) |
|  5.1\* | [Opinion of Pearl Cohen Zedek Latzer Baratz regarding the validity of the Ordinary Shares being registered](http://www.sec.gov/Archives/edgar/data/2102720/000121390026066188/ea027016609ex5-1.htm) |
|  5.2\* | [Opinion of Ellenoff Grossman and Schole LLP](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex5-2.htm) |
|  10.1\*# | [Tarsier Pharma Global Share Incentive Plan (2018) and Amendment No.1 thereto](http://www.sec.gov/Archives/edgar/data/2102720/000121390026066188/ea027016609ex10-1.htm) |
|  10.2\*# | [Tarsier Pharma Global Share Incentive Plan (2026)](http://www.sec.gov/Archives/edgar/data/2102720/000121390026066188/ea027016609ex10-2.htm) |
|  10.3\*# | [Employment Agreement between the Registrant and Daphne Haim-Langford, Ph.D.](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex10-1.htm) |
|  10.4\*# | [Employment Agreement between the Registrant and Zohar Milman, M.Sc.](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex10-2.htm) |
|  10.5\*# | [Amended and Restated Consulting Agreement, dated June 1, 2026, between the Registrant and Ron Neumann, M.D.](http://www.sec.gov/Archives/edgar/data/2102720/000121390026066188/ea027016609ex10-5.htm) |
|  10.6\*# | [Services Agreement, dated January 1, 2026, between the Registrant and Natig for services of Arie Ganot](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex10-4.htm) |
|  10.7\* | [Offer Letter between the Registrant and Sascha Bucher](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex10-5.htm) |

---

---

| | |
|:---|:---|
|  **Exhibit No.** | **Description of document** |
|  10.8\* | [Offer Letter between the Registrant and Susan Benton](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex10-6.htm) |
|  10.9\* | [Board Member Agreement between the Registrant and Richard Eiswirth](http://www.sec.gov/Archives/edgar/data/2102720/000121390026066188/ea027016609ex10-9.htm) |
|  10.10\*\*+ | [License Agreement, entered into on January 27, 2016](ea027016611ex10-10.htm) |
|  10.11\* | [Declaration of Receipt of Loan](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex10-8.htm) |
|  10.12\*# | [Form of Indemnification Agreement between the Registrant and its directors and executive officers](http://www.sec.gov/Archives/edgar/data/2102720/000121390026066188/ea027016609ex10-12.htm) |
|  14.1\* | [Code of Business Conduct and Ethics of the Registrant](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex14-1.htm) |
|  21.1\* | [List of Subsidiaries of the Registrant](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex21-1.htm) |
|  23.1\* | [Consent of Somekh Chaikin, a Member Firm of KPMG International](http://www.sec.gov/Archives/edgar/data/2102720/000121390026066188/ea027016609ex23-1.htm) |
|  23.2\* | [Consent of Pearl Cohen Zedek Latzer Baratz (included in Exhibit 5.1)](http://www.sec.gov/Archives/edgar/data/2102720/000121390026066188/ea027016609ex5-1.htm) |
|  23.3\* | [Consent of Ellenoff Grossman & Schole LLP (included in Exhibit 5.2)](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex5-2.htm) |
|  24.1\* | [Power of Attorney (included on the signature page of this Registration Statement)](http://www.sec.gov/Archives/edgar/data/2102720/000121390026066188/ea0270166-09.htm#T991) |
|  99.1\* | [Audit Committee Charter](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex99-1.htm) |
|  99.2\* | [Compensation Committee Charter](http://www.sec.gov/Archives/edgar/data/2102720/000121390026066188/ea027016609ex99-2.htm) |
|  99.3\* | [Nominating and Corporate Governance Committee Charter](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex99-3.htm) |
|  99.4\* | [Insider Trading Policy of the Registrant](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex99-4.htm) |
|  99.5\* | [Clawback Policy of the Registrant](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex99-5.htm) |
|  99.6\* | [Consent of Richard Eiswirth as director nominee](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex99-6.htm) |
|  107\* | [Filing Fee Table](http://www.sec.gov/Archives/edgar/data/2102720/000121390026058235/ea027016608ex-fee.htm) |

---

____________

\* Previously filed.

\*\* Filed herewith.

+ Portions of this exhibit have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K. The Registrant undertakes to furnish a copy of all omitted schedules and exhibits to the SEC upon its request.

# Indicates a management contract or other compensatory plan or arrangement.

#### Item 9. Undertakings
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

The undersigned registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• To provide the underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

#### SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement on Form F-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in Zichron Yaacov, Israel, on June 16, 2026.

---

| | |
|:---|:---|
|  **Tarsier Pharma Ltd.** | **Tarsier Pharma Ltd.** |
|  By: | */s/ Daphne Haim-Langford*  |
|  Name: | Daphne Haim-Langford |
|  Title: | Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
|  **Person** | **Capacity** | **Date** |
|  */s/ Daphne Haim-Langford*  | Chief Executive Officer and Director | June 16, 2026 |
|  Daphne Haim-Langford | (*Principal Executive Officer*) |  |
|  */s/ Arie Ganot* | Chief Financial Officer | June 16, 2026 |
|  Arie Ganot | (*Principal Financial and Accounting Officer*) |  |
|  *\** | Director | June 16, 2026 |
|  Susan Benton |  |  |
|  *\** | Director | June 16, 2026 |
|  Sascha Bucher |  |  |
|  *\** | Director | June 16, 2026 |
|  Atul Raut |  |  |

---

---

| | | |
|:---|:---|:---|
|  *\**By: | */s/ Daphne Haim-Langford*  | June 16, 2026 |
|  | *Attorney*-in-Fact |  |

---

#### SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES
Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, Puglisi & Associates, the duly authorized representative in the United States of Tarsier Pharma Ltd. has signed this registration statement on June 16, 2026.

---

| | |
|:---|:---|
|  Puglisi & Associates | Puglisi & Associates |
|  By: | */s/ Donald J. Puglisi*  |
|  Name: | Donald J. Puglisi |
|  Title: | Managing Director |

---

## Exhibit 10.10

**Exhibit 10.10**

**LICENSE AGREEMENT**

**THIS AGREEMENT** (the "**Agreement**") is entered into effective as of January 27, 2016 (the "**Effective Date**") by and between Tarsius Pharma Ltd. (or as shall be approved by the Israeli Companies Registrar) to be incorporated as a private limited liability company duly organized in Israel (the "**Company**") and Prof Yehuda Shoenfeld, I.D [__] from [___________], Israel, and Prof Miri Blank I.D [__] from [___________], Israel (together: the "**Inventors**"). Each of the Company and the Inventors (jointly and severally) may be referred to herein as a "**Party**", and together as the "**Parties**".

**RECITALS**

**WHEREAS**, the Inventors jointly invented the Invention during the term of their employment with Sheba (as such term is defined below); and

**WHEREAS**, following and according to the Sheba Agreement (as defined below) the Inventors have received a waiver from Sheba of its ownership rights in and to the Invention and the Patents; and

**WHEREAS,** the Inventors desire to license to the Company and the Company desires to license from the Inventors for the purpose of developing and commercializing certain products which will be based on the Patents and the rights licensed herein in the Agreed Field (as defined below) (the "**Products**");

**NOW, THEREFORE**, the Parties hereby agree as follows:

1. <u>DEFINITIONS</u>. For the purpose of this Agreement, the following definitions apply:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1. "**Agreed Field**" local delivery of Tuftsin Phosphrylcoline for any ophthalmic indications.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2. "**Founders Agreement**" agreement entered between Dr. Daphne Haim Langford, the Inventors
and Van Leer Xenia GP on January 27, 2016.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3. "**Intellectual Property**" means all worldwide (i) patents and patent applications (including
the Patents), patent rights, designs, and inventions (whether patentable or not); (ii) trademarks (whether registered or not), trade dress,
trade names and logo; (iii) rights associated with works of authorship including, copyrights, copyright applications, copyright restrictions,
mask work rights, mask work applications, and mask work registrations; (iv) rights relating to the protection of trade secrets, know-how
and confidential information; (v) rights analogous to those set forth herein and any other proprietary rights relating to intangible property;
and (vi) divisions, continuations, renewals, reissues, and extensions of the foregoing (as applicable) now existing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4. "**Invention**" means the "Tuftsin-Pshosphorylcholine for Treating Autoimmune Diseases"
as detailed in Appendix A to the Sheba Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5. "**Lien**" means any lien, pledge, mortgage, deed of trust, security interest, claim, lease,
charge, option, easement, servitude, right of first refusal, right of first offer, proxy, voting trust or agreement or other similar encumbrance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6. "**Patents**" means those patents and patent applications relating to the Invention as
specified in  **<u>Exhibit A</u>** attached hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7. "**Sheba Agreement**" means the agreement executed by and between the Inventors and Chaim
Sheba Integrated Medical Center and Medical Research Infrastructure Development and Health Services Fund by Sheba Medical Center (together:
" **Sheba**") on October 26, 2015, attached hereto as  **<u>Exhibit B</u>** .

2. <u>GRANT OF LICENSE</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1. Subject to the terms and conditions of this Agreement, the Inventors hereby grant to the Company, effective
as of the Effective Date, an exclusive, worldwide, irrevocable, royalty-free, fully paid, transferable and sub-licensable license to use,
develop and commercialize the Invention in the Agreed Field, and to design, develop, make and have made, use, sell and offer for sale
the Products (the "**License** "). Notwithstanding the above, and anything else written in this Agreement or in the Founders
Agreement, the Inventors are not providing under this Agreement and will not provide in the future to the Company any right not granted
to them under the Sheba Agreement. To the extent that anything in this Agreement shall be interpreted as granting the Company any rights
in excess of the Sheba Agreement, the Parties affirmatively agree and confirm that they had no intention to license or receive such rights
and that such license shall be null and void.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2. No other, further or different license is hereby granted or implied. The License granted by the Inventors
hereunder is for the limited scope specified herein, and shall not include any other rights not expressly provided in this Agreement.
For the avoidance of doubt it is clarified that the Inventors shall be entitled to assign their rights under the Sheba Agreement to any
third party or to grant any third party with a license similar to the License granted under this Agreement, provided that the Inventors
(or any of their respective assignees or licensors) shall not be entitled to grant any license to the Invention in the Agreed Field and
provided further that the Company's rights under this Agreement shall remain in full force and effect following such assignment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3. The Parties shall take any reasonable action, at the Company's cost and expense, including signing
and executing any reasonably required document, in order to register (to the extent possible) the Company's rights under the License
in the Patent offices in the relevant jurisdictions.

3. <u>TERM OF AGREEMENT</u> 

The License granted under this Agreement is irrevocable and perpetual and therefore this Agreement and the License as granted hereunder shall continue without limitation of duration.

4. <u>CONSIDERATION</u> 

In consideration for the License granted hereunder the Inventors (together) shall be entitled to receive holdings in the Company, upon its incorporation, representing twenty percent (20%) of the Company's issued and outstanding share capital on a fully diluted basis ("**Inventors' Holdings**"). The Inventors' Holdings shall be allocated as set forth in the Founders Agreement**.** 

For the avoidance of doubt, it is hereby clarified that the said consideration shall be the sole and absolute consideration granted to the Inventors under this Agreement, and that the Inventors shall be solely responsible for any consideration Sheba may be entitled to receive under the Sheba Agreement.

5. <u>REPRESENTATIONS AND WARRANTIES OF THE INVENTORS</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1. To the knowledge of the Inventors no other third party is entitled to be listed as an Inventor of the
Patents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2. To the knowledge of the Inventors, other than Sheba, no other person or third parties claimed any ownership
rights to the Invention including without limitation any employees, consultants, service providers or otherwise who may have been involved
in the development of the Invention.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3. Except as set forth in the Sheba Agreement, the Inventors are sole and exclusive owners, free and clear
of any Lien or written notice of adverse claims from any other third party, all right, title and interest in and to the Invention.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4. As of the date they obtained ownership of the Invention, the Inventors have taken all commercially reasonable
actions to protect their rights in, and the validity and/or value of the Invention. The Inventors have protected the confidentiality of
all trade secrets relating to the Invention, and have disclosed such trade secrets only pursuant to customary, written confidentiality
agreements. Other than the License granted under this Agreement and the license detailed in the Sheba Agreement, the Inventors have not
granted any license and any other right in the Invention in the Agreed Field to any third party, and will not grant, assign or transfer
such license or other right in the Agreed Field to any third party without the prior written consent of the Company, except that nothing
in this Agreement is intended to limit the Inventors from granting identical rights to the rights granted to the Company under this Agreement,
provided such rights are not in the Agreed Field. For the avoidance of doubt, it is hereby clarified that the Inventors shall not be entitled
to make any use, and shall not have any right, in the Invention in the Agreed Field, without the prior written consent of the Company.
Except as set forth in the Sheba Agreement, the Inventors are not obligated or under any liability whatsoever to make any payments by
way of royalties, fees or otherwise to any third party in connection with the Invention in the in the Agreed Field or the Products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5. To the knowledge of the Inventors, the Inventors have not violated or infringed or are violating or infringing
any of the Intellectual Property of any other person or entity (including without limitation, any former employer) and they have not received
any communications alleging any such violation or infringement. The Inventors are unaware of any third party, which is infringing upon,
violating, misappropriating or making an unauthorized use or disclosure of, the Invention. To the knowledge of the Inventors, there is
no third party, which has the right to assert any claim regarding the ownership of the Invention and the Inventors shall provide prompt
written notice to the Company of any claim by a third party that the License granted hereunder infringes the Intellectual Property rights
of any third party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.6. To the knowledge of the Inventors, neither the execution and delivery of this Agreement, nor the carrying
on of the Company's business (including the development of the Products), will conflict with or result in a breach of the terms,
conditions or provisions of, or constitute a default under, any contract, covenant or instrument under which the Inventors are obligated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.7. Except for the representations made by the Inventors as set forth in Sections ‎ 5.1
to ‎ 5.6 above, and to the maximum extent permitted by applicable law,
Sheba, Inventors, VLX and TPCera (as defined below) and their respective shareholders, directors, employees, consultants, agents or representatives
(collectively the "**Indemnifying Parties**") make no representations or warranties of any kind, expressed or implied,
with respect to the Invention or the Patents. In particular, Indemnifying Parties make no express or implied warranties of merchantability
or fitness for a particular purpose. In addition, nothing in this Agreement may be deemed a representation or warranty by any of the Indemnifying
Parties as to the validity of any of the Patents or their registerability or of the accuracy, safety, efficacy, or usefulness, for any
purpose, of the Invention. To the extent permitted by applicable law, the Indemnifying Parties shall not have any liability whatsoever
toward the Company, its shareholders or to any third party for or on account of any injury, loss, or damage, of any kind or nature whether
direct or indirect, sustained by the Company or by any third party, for any damage assessed or asserted against the Company, or for any
other liability incurred by or imposed upon the Company or any other person or entity, directly or indirectly arising out of or in connection
with or resulting from the exercise of the License, including, (i) the production, manufacture, use, practice, lease, or sale of any product;
(ii) the use of the License granted herein; or (iii) any advertising or other promotional activities with respect to any of the foregoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.8. Subject to the limitation set forth in Section ‎ 5.9
to Section ‎ 5.12, the Inventors shall indemnify the Company (and its
employees, officers, directors, successors and assigns) and hold the Company (and its employees, officers, directors, successors and assigns)
harmless from and against, all direct loss, cost, damage, liability and expense (including reasonable attorney's fees and expenses)
(" **Loss** "), arising from (i) any infringement by the Inventors of any of the representations and warranties made under
this Section 5; and (ii) any claim of any third party that the Inventors misrepresented their right and entitlement to enter into this
Agreement and to grant the License (the "**Remedy** ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.9. In no event shall Indemnifying Parties be liable to the Company or any of its affiliates or to any third
party for any incidental, special, punitive or exemplary damages suffered or incurred by the Company, its shareholders or its affiliates
or any third party, whether based upon a claim or action of contract, warranty, negligence or tort, or otherwise, arising out of this
Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.10. The Remedy shall be the Company's and its shareholders sole and exclusive remedy against the Indemnifying
Parties and shall constitute full satisfaction of the Indemnifying Parties liability towards the Company and its shareholders due to any
breach and/or misrepresentation of any covenant, warranty, undertaking and representation made under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.11. The representations and warranties detailed in this Agreement shall remain in full force and effect for
a period of 24 (twenty four) months as of the Effective Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.12. Notwithstanding the above, the indemnification obligations set forth in this Section ‎ 5
shall be limited to 100% (one hundred percent) of the securities of the Company received by the Inventors under this Agreement. Such aggregate
liability shall be satisfied by surrender and transfer of such securities to Company, which number shall be equal to the amount of Loss
for which indemnification is due divided by the fair market value (as determined in good faith by the Board) of such securities at such
time, provided that in no event shall the Inventors be obligated to surrender a number of securities larger that the number granted to
them under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.13. The Company shall provide prompt notice of any such infringement or third party's claim and shall
give the Inventors the right to defend any such claim, and shall cooperate fully in such defense at the Inventors costs and expenses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.14. The Inventors shall provide prompt notice to the Company of any claim first known to them relating to
the Invention

6. <u>COMPLEMENTARY PROVISIONS</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1. Subject to the limitation of the Sheba Agreement, and any other document relating to the ownership of
intellectual property of Sheba employees or relating to the work of the Inventors in Sheba (collectively the "**IP Documents** "),
the Inventors undertake to provide the Company with any information and documentation relating to the Invention, as may be necessary for
the use of the License or may be reasonably required by the Company. Without derogating the generality of the foregoing, upon the execution
of this Agreement the Inventors will deliver to the Company any and all available technical data and information relating to the Invention,
including drawings, schematics, product specifications, information concerning research and development work, and the Patent applications
and all ancillary documents thereto to the extent they are entitled to deliver such information under the IP Documents. Without derogating
from the above, it is agreed by the Parties that within thirty (30) days as of the Effective Date, Prof Miri Blank together with the management
of the Company shall decide on the identity of the manufacturer of the Tuftsin-Pshosphorylcholine. In making this decision Prof Miri Blank
and the management of the Company shall take into consideration all relevant parameters including without limitation the costs of manufacturing,
quality and qualifications of the manufacturer, and availability for manufacturing of the Tuftsin-Pshosphorylcholine etc'. Following
this initial selection, and in the event that the Company is not satisfied with the performance of the manufacturer, Company shall be
entitled to replace the manufacturer of the Tuftsin-Pshosphorylcholine following consultation with Prof Miri Blank. The selected manufacturer
shall receive from Prof Miri Blank, the synthesis protocol for the manufacturing the Tuftsin-Pshosphorylcholine (the "**Protocol** ").
The Protocol shall remain the exclusive property of the Inventors (and following the establishment of TPCera and shall be assigned thereto).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2. TPCera and in the event that TPCera shall not be established the Inventors (or any other third party which
shall be decided upon by the Inventors) shall bear any and all costs and expenses related to and associated with pursuing the necessary
registration, maintenance, prosecution or renewal of the Patents in the territories in which the Patents have currently been filed (as
more detailed in Exhibit A) including, without limitations, annual fees, registration expenses, any post issuance procedures, etc., except
that nothing herein shall obligate Inventors (or their successive assignees or licensors to pursue any of the patents). Immediately following
the establishment of TPCera or any other company that will take ownership on the IP, the obligation set forth in this Section ‎ 6.2
shall transfer to TPCera, and the Inventors shall no longer be responsible or liable for any of the obligation set forth in this Section ‎ 6.2. Notwithstanding the above, it is hereby agreed that a onetime
payment in the amount of 915$, due for the registration of the Patent in China by January 27, 2016, shall be paid by the Company prior
to such date, and that TPCera or any other company that will take ownership on the IP shall reimburse the Company for such payment within
no later than 24 months as of such payment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3. In the event that the Inventors will inform the Company that it does not intend to pay maintenance fee
and/or patent annuity in order to keep the Patent in force in one or more countries, than the Company shall be entitled to pay the maintenance
fee and/or the patent annuity, as the case may be, and to file, prosecute, maintain and enforce the Patent rights in the Inventors and/or
TPCera's name. Inventors shall provide the Company, at the Company's cost and expense, or its authorized attorneys, agents,
or representatives reasonable assistance as necessary for the Company to exploit its right under this Section ‎ 6.3.
It is hereby agreed that upon such event, the Company shall become the sole owner of such Patent, and shall grant the Inventors exclusive
license to use such Patent in any field, other than the Agreed Field.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4. Company hereby grants TPCera (or any other Company to whom the Inventors may assign their rights under
the Invention) a non-exclusive, non-assignable, irrevocable, royalty-free license to any and all patents and patent applications, which
shall be: (i) created or developed by Company following the Effective Date; and (ii) related to the Tuftsin-Pshosphorylcholine, to the
extent they are required to practice the Invention, to make, have made, use, lease, commercialize, continue to develop technology relating
to, offer for sale, sell, import, export, and otherwise dispose of any and all products developed by TPCera (or any other Company to whom
the Inventors may assign their rights under the Invention) in all countries where such patents have been issued, with no rights to grant
sub-licenses except to: (i) subcontractors for the purpose of: (a) manufacturing products to end customers; and (b) importing, exporting,
using, leasing, offering for sale, selling and otherwise disposing of products; and (ii) direct and indirect customers of Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5. TPCera (or any other Company to whom the Inventors may assign their rights under the Invention) hereby
grants Company a non-exclusive, non-assignable, irrevocable, royalty-free license to any and all patents and patent applications which
shall be created or developed by TPCera (or any other Company to whom the Inventors may assign their rights under the Invention) following
the Effective Date to the extent they are required to practice the Invention in the Agreed Field, to make, have made, use, lease, commercialize,
continue to develop technology relating to, offer for sale, sell, import, export, and otherwise dispose of any and all products developed
by Company, in all countries where such patents have been issued, with no rights to grant sub-licenses except to: (i) subcontractors for
the purpose of: (a) manufacturing products to end customers; and (b) importing, exporting, using, leasing, offering for sale, selling
and otherwise disposing of products; and (ii) direct and indirect customers of Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6. **Patent Protection** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6.1 The Inventors (or any third party to whom the Patents shall
be assigned) (the "**Patent Owner**") and Company shall each inform the other promptly in writing of any alleged infringements
by a third party of the Patents in the Agreed Field in any country, together with any available written evidence of such alleged infringement . Upon such an event, the Patent Owner shall have the first right in its own name and at its own expense to initiate any legal action and
enforce the Patents against any infringement of such Patents (regardless if such infringement is in the Agreed Filed or not). For the
avoidance of doubt, it is clarified that the Patent Owner shall be entitled to receive all proceeds generated from such legal action.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6.2 In the event that the Patent Owner decides not to exercise its
right to initial legal proceedings as detailed in Section ‎ 6.4.1,
and in the event that the alleged infringement is solely in the Agreed Field, Company shall be entitled to initiate legal proceedings
against infringing third party provided that the Company shall give careful consideration to the views of Patent Owner in making its
decision whether or not to initiate any legal action. Company shall continuously keep Patent Owner reasonably apprised of all developments
in the action and shall continuously provide Patent Owner with full information and copies of all documents relevant to the proceedings,
including, all documents filed with the courts by the parties to the legal action(s) and all material correspondence with the other parties
to the proceedings, and shall seek Patent Owner input and approval on any substantive submissions or positions taken in the litigation
regarding the scope, validity or enforceability of the Patents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6.3 If Patent Owner shall determine that the legal actions taken
by the Company may adversely affect Patent Owner's rights, Patent Owner shall be entitled to appoint its own counsel to represent
it in such litigation. Patent Owner shall bear all payments for such legal representation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6.4 If the Company elects to commence an action as described above and Patent Owner is a legally indispensable
party to such action (being the registered owner of the infringed patent rights), Company, at the Patent Owner's expense, may be
joined as a co-plaintiff, provided that all the following conditions shall be fulfilled:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Company shall continuously provide Patent Owner with full information and copies of all documents materially relevant to the proceedings, including, all documents filed with the courts by the parties to the legal action(s) and all material correspondence with the other parties to the proceedings, as well as all drafts of written submissions relating to such legal action that are sent to the Company for review, and all Patent Owner's material comments in respect thereof will be taken into account;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) if Patent Owner shall determine that a conflict of interest exists between the Company and Patent Owner, Patent Owner shall be entitled, at its own expense, to appoint its own counsel to represent it in such litigation and the Company shall make best efforts to ensure that such counsel chosen by Patent Owner is fully informed and receives all material necessary to adequately participate in such action; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the Company shall bear all costs, expenses and awards incurred by or awarded against Patent Owner, with respect to any action filed against Patent Owner alleging that an action initiated by the Company pursuant to the terms of this Section 6.4 was anticompetitive, malicious, or otherwise brought for an improper purpose, whether by a counterparty to such aforementioned action or by any third party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6.5 If Patent Owner is not required by law to be joined as a co-plaintiff, Patent Owner, to the extent permitted
by law, and at its own cost, may elect to join the action as a co-plaintiff at its own initiative and shall jointly control the action
with the Company. Irrespective of whether Patent Owner joins any such action as described above it shall provide reasonable cooperation
to the Company. The Company shall reimburse Patent Owner for any costs it incurs as part of an action brought pursuant to this Section
where Patent Owner has not elected to join the action as a co-plaintiff at its own initiative.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6.6 No settlement, consent judgment or other voluntary disposition
of an infringement suit may be entered without the consent of Patent Owner, which consent shall not be unreasonably withheld, conditioned
or delayed. For the avoidance of doubt and notwithstanding anything to the contrary herein, should Patent Owner bring an action as set
forth in this Section 6.4, it shall have the right to settle such action by licensing the Patent, or part of it, to the alleged infringer,
provided such license shall not apply to the Agreed Field.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6.7 If either Patent Owner or Company commences an action and then decides to abandon it, such party will
give timely notice to the other party. The other party may continue the prosecution of the suit after both parties agrees in good faith
on the sharing of expenses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7. In the event that any business opportunity related to the business of Company in the Agreed Field, including
the Products, shall come to the Inventors' knowledge, the Inventors shall promptly notify the Company of such opportunity. The Inventors
shall not appropriate for themselves or for any other person or entity other than the Company, any such opportunity, except with the express
written consent of the Company, in advance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.8. The Company shall not, directly or indirectly, as owner, partner, joint venturer, shareholder, service
provider, broker, agent, director, licensor or in any other capacity whatever engage in, become financially interested in, be engaged
by, or have any connection with any business or venture that is engaged in activities involving Tuftsin-Pshosphorylcholine and competing
with TPCera provided that involvement in the Agreed Field shall not be deemed a violation of this Section ‎ 6.6.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.9. The Company shall not enter into any agreement which is knowingly and deliberately intended to limit the
progress of TPCera, including without limitation any agreement which shall limit the ability of TPCera to manufacture the Tuftsin-Pshosphorylcholine.

6 <u>CONFIDENTIALITY</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4 "**Confidential Information**" means any information and documentation, including business
and technical data, which relates to the Invention, the Products, the Inventors' Intellectual Property and the Company, including
such information which disclosed prior the execution of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5 Each of the parties hereto agrees not to use the Confidential Information and not to publish, disclose
or transfer any Confidential Information to any third party unless such disclosure is specifically consented to in writing by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6 Each of the parties hereto will take all reasonable steps to protect the security of and avoid the unauthorized
disclosure and use of the Confidential Information and to prevent it from falling into public domain or the possession of unauthorized
persons. Each of the parties hereto will notify the other party hereto of any misuse, misappropriation or unauthorized disclosure of Confidential
Information that may come to their attention.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7 These non-disclosure and non-use obligations shall apply without limitation of time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.8 Each of the parties hereto acknowledges that the unauthorized use, disclosure or transfer of Confidential
Information will: (i) substantially diminish the value to the other party hereto of the Confidential Information; (ii) render the Company's
remedy at law to such unauthorized use, disclosure or transfer inadequate; and (iii) cause irreparable injury in a short period of time.
If either party will breach any of its obligations with respect to Confidential Information, the other party shall be entitled to equitable
relief to protect its interests therein, including, but not limited to, preliminary and permanent injunctive relief.

7 <u>INVENTORS' NEW COMPANY</u>

Since it is the Inventors' intention to form a new company which shall be the owner of the Invention and the Inventors' Intellectual Property, named TPCera or other, ("**TPCera**"), it is hereby agreed that the Inventors shall be obligated, upon the formation of the TPCera and as a condition thereto, to have the TPCera ratify and approve the terms of this Agreement. For the avoidance of doubt, it is clarified that such ratification and approval shall not release the Inventors from any of their representations, warranties and/or any other undertaking under this Agreement.

8 <u>MISCELLANEOUS</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4 <u>Entire Agreement</u>. This Agreement constitutes the entire understanding of the Parties with respect
to the subject matter hereof, and supersedes all prior agreements and understandings with respect thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.5 <u>Independent Contractors</u>. The Parties' relationship under this Agreement will be that of independent
contractors, and nothing herein shall be deemed to create any form of principal-agent relationship, partnership, employer-employee relationship
or joint venture between the Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.6 <u>Amendment</u>. No amendment, modification or alteration of the terms or provisions of this Agreement,
including any Exhibits hereto, shall be binding unless the same shall be in writing and duly executed by the Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.7 <u>No Assignment</u>. This Agreement is assignable and transferable by any Party without the prior written
consent of the other Party. This Agreement shall inure to the benefit of, and shall be binding upon the assigns, successor in interest,
personal representatives, estates, heirs and legatees of each of the Parties hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.8 <u>Notice</u>. Any notice, demand, consent or other communication under this Agreement shall be in writing
addressed to the other Party at its address on the first page to this Agreement, or to such other address as such Party shall have theretofore
furnished by like notice, and either served personally, sent by registered or certified first class mail, postage prepaid, sent by facsimile
transmission, or delivered by reputable commercial courier. Such notice shall be deemed given (i) when so personally delivered, or
(ii) if mailed as aforesaid, four (4) days after the same shall have been posted, or (iii) if sent by facsimile, one (1) business day
following the date on which the transmission of the facsimile was confirmed, or (iv) if sent by reputable commercial courier, four (4)
days after the same shall have been sent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.9 <u>Delays or Omissions; Waiver</u>. No delay or omission to exercise any right, power or remedy accruing
to either Party upon any breach or default by the other Party under this Agreement shall impair any such right or remedy, nor shall it
be construed to be a waiver of any such breach or default, or any acquiescence therein or in any similar breach or default thereafter
occurring.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.10 <u>Counterparts</u>. This Agreement may be executed in any number of counterparts, each of whom shall
be deemed an original but all of which together shall constitute one and the same instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.11 <u>Governing Law and Jurisdiction</u>. This Agreement shall be governed by and construed solely in accordance
with the laws of the State of Israel. The Parties hereto submit to the exclusive jurisdiction of the courts of the Tel Aviv - Jaffa District
in Israel, over any dispute or claim arising out of or in connection with this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.12 <u>Severability</u>. In the event that any provision of this Agreement is rendered invalid or otherwise
unenforceable by any competent judicial or government authority, such invalidity or unenforceability shall not affect the validity or
enforceability of any other provision of this Agreement, and the invalid provision shall be deemed amended to the fullest extent allowable
by applicable law to achieve the purposes of said provision.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.13 <u>Headings</u>. The headings and titles to the articles of this Agreement are inserted for convenience
only and shall not be deemed a part hereof or affect the construction or interpretation of any provision hereof.

**IN WITNESS WHEREOF**, the Parties hereto have caused this Agreement to be executed as of the Effective Date.

---

| | | | |
|:---|:---|:---|:---|
| **Dr. Daphne Haim – Langford on behalf of** | **Dr. Daphne Haim – Langford on behalf of** | **The Inventors** | **The Inventors** |
| **Tarsius Pharma Ltd.** (to be incorporated) | **Tarsius Pharma Ltd.** (to be incorporated) | | |
| By: | /s/ Daphne Haim-Langford | Name : | Prof. Yehuda Shoenfeld |
| (Signature) | (Signature) |  |  |
|  | Daphne Haim-Langford, Chief Executive Officer | Signature: | /s/ Yehuda Shoenfeld |
| (Print Name & Title) | (Print Name & Title) |  |  |
|  |  | Name : | Prof. Miri Blank |
|  |  | Signature: | /s/ Miri Blank |

---

EXHIBIT A

**<u>List of Patents and Patent Applications</u>**

Exhibit A-1

**CONFIDENTIAL**

**Patent Family Report**

---

| | | | |
|:---|:---|:---|:---|
| **File No.:** | SBA/006 | **Assignee:** | Tel Hashomer Medical Research Infrastructure and Services Ltd. |
| **Priority:** | US Prov. | 05/Feb/2013 | 61/760668 |
| **Title:** | PHOSPHORYLCHOLINE-BASED AGENTS AND USE THEREOF | PHOSPHORYLCHOLINE-BASED AGENTS AND USE THEREOF | PHOSPHORYLCHOLINE-BASED AGENTS AND USE THEREOF |
| **Abstract:** | The present invention provides synthetic phosphorylcholine (PC)-conjugates and pharmaceutical compositions, particularly vaccines comprising same for the prevention or treatment of autoimmune diseases. In particular, the synthetic PC-conjugates of the present invention are effective in preventing or treating autoimmune diseases associated with pathological inflammation. | The present invention provides synthetic phosphorylcholine (PC)-conjugates and pharmaceutical compositions, particularly vaccines comprising same for the prevention or treatment of autoimmune diseases. In particular, the synthetic PC-conjugates of the present invention are effective in preventing or treating autoimmune diseases associated with pathological inflammation. | The present invention provides synthetic phosphorylcholine (PC)-conjugates and pharmaceutical compositions, particularly vaccines comprising same for the prevention or treatment of autoimmune diseases. In particular, the synthetic PC-conjugates of the present invention are effective in preventing or treating autoimmune diseases associated with pathological inflammation. |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Country** | **Application No.** | **Filing Date** | **Patent No.\Pub. No.** | **Issue Date\Pub. Date** | **Status** |
| Australia | 2014213631 | 05/Feb/2014 |  |  | filed |
| Canada |  | 05/Feb/2014 |  |  | filed |
| China | 2014800201992 | 05/Feb/2014 |  |  | filed |
| Europe | 14749245.8 | 05/Feb/2014 |  |  | filed |
| India | 2479/MUMNP/2015 | 05/Feb/2014 |  |  | filed |
| PCT | PCT/IL2014/050124 | 05/Feb/2014 | WO2014/122646 | 14/Aug/2014 | expired |
| US Prov. | 61/590830 | 26/Jan/2012 |  |  | expired |
| US Prov.-1 | 61/760668 | 05/Feb/2013 |  |  | expired |
| USA | 14/766108 | 05/Feb/2014 | projected | 24/Dec/2015 | filed |

---

22/Nov/15

Exhibit A-2

EXHIBIT B

**<u>Sheba Agreement</u>**

Pursuant to the Sheba Agreement, Sheba has waived and relinquished any and all ownership rights it may have in the Intellectual Property in exchange for the consideration set forth therein. Pursuant to that same Agreement, the inventors granted back to Sheba a non-exclusive, royalty-free, and irrevocable license to use the Intellectual Property solely for academic or scholarly purposes.